Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 85

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 5
Chunk 85
---
  Avenanthramides for Potential Applications in Inflammation Based Diseases                                                             
  - Phase 1-2a as a potential anti-inflammatory product. Study being conducted by Montreal Heart Institute. Clinical trial is expected  
  to have included 96 subjects/patients (72 healthy volunteers in Phase 1 and 24 patients in Phase 2) upon completion. Enrollment for   
  Phase 1 started mid-December 2023. Ceapro is the sponsor.                                                                             
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  our pipeline activities which consist of pre-clinical work.                                                                           

  Trend Information  
 ─────────────────────

Other than as disclosed below and elsewhere in this
Annual Report, we are not aware of any trends, uncertainties, demands, commitments, or events that are reasonably likely to have a material
effect on our net revenue, income from continuing operations, profitability, liquidity, or capital resources, or that would cause reported
financial information not necessarily to be indicative of future operating results or financial condition.

Financial Risk Factors and Other Instruments

The nature and extent of our exposure to risks arising
from financial instruments, including credit risk, liquidity risk and market risk (share price risk) and how we manage those risks are
described in note 23 to the Company’s annual audited consolidated financial statements as of December 31, 2024 and 2023 and for
the years ended December 31, 2024, 2023 and 2022.

The consolidated financial statements filed as part
of this Annual Report on Form 20-F are presented under “ Item 18. - Financial Statements”.

  Critical Accounting Estimates  

See Item 18. “ Financial Statements”.

Item 6. Directors, Senior Management and Employees